translation agency

PR Newswire
Parker Hughes Institute Granted Patent for New Anti-AIDS Drug: Temporarily Closes HIV Clinic in Preparation for Stampidine Clinical Trial

March 28, 2002
ROSEVILLE, Minn. -- On February 26, 2002 the U.S. Patent and Trademark Office granted Parker Hughes Institute a patent (U.S. patent No. 6,350,736) for Stampidine, a new anti-AIDS drug developed at the institute.

Parker Hughes Institute has completed all pre-clinical research and development related to Stampidine and is getting ready to seek FDA approval to initiate clinical trials. Parker Hughes Institute expects to receive that approval and begin clinical trials of Stampidine within the next three to six months.

Minnesota Comprehensive Care Center, the HIV/AIDS clinic operated by the Institute, has been temporarily closed so that the staff may focus on all the necessary preparations needed to initiate the Stampidine clinical trial.

"There's a lot of hard work that needs to be done in order to prepare for this clinical trial and we have made the decision that for now our HIV clinic will focus solely on the Stampidine trial so that we can continue to develop this life saving anti-AIDS drug without delay," said Fatih Uckun, President and Director of Parker Hughes Institute.

SOURCE Parker Hughes Institute

Web Site: http://www.parkerhughes.org



www.aegis.org